13/03/2024 – AB Science today announced the publication of new preclinical results for masitinib in neurodegenerative diseases Download PDF Post navigationPreviousPrevious post:Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentNextNext post:AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSRelated PostsPositive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024June 26, 2024 CGM – Q&A documentJune 26, 2024Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024AB Science webcast of May 30, 2024May 30, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024
